Our Pipeline of therapeutic candidates

CB-24

CROTOXIN

  • Nicotinic antagonist
  • Bipartite self-targeting drug anti-inflammatory
  • Targeting NSCLC & solid tumors
  • 2 parts of Phase I complete, 3rd pending
PHASE II READY

CB-6

COBRAMINE

  • Protein kinase C inhibitor
  • Anti-inflammatory action
  • Orally bioavailable peptide
  • Targeting chronic kidney disease
PHASE Ib READY

CB-24/CB-6

CTC-310

  • Composite product
  • Targeting pancreatic, colon and hematological Cancers
  • Phase Ia completed
PHASE Ib READY

CB-4

CROTAMINE

  • Cell penetrating peptide
  • Orally bioavailable
  • Active against melanoma
  • Potential gene therapy applications
PRECLINICAL